Production of IL-1, IL-6, IL-21, IL-17, and IL-22 enhances inflammatory condition among MS patients, while regulatory T-cell releasing cytokines like IL-10 may alleviate this condition [7, 8, 11]. This evidence concerns the gene IL17A and myeloid sarcoma.